Base de dados : MEDLINE
Pesquisa : B03.510.024.100.313 [Categoria DeCS]
Referências encontradas : 36 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 36 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29255098
[Au] Autor:Little P; Stuart B; Wingrove Z; Mullee M; Thomas T; Johnson S; Leydon G; Richards-Hall S; Williamson I; Yao L; Zhu S; Moore M
[Ad] Endereço:Primary Care Group (Little, Stuart, Wingrove, Mullee, Thomas, Johnson, Leydon, Williamson, Moore); Health Economic Analyses Team (Yao, Zhu), Primary Care and Population Sciences Unit, University of Southampton; Patient and Public Involvement Collaborator (Richards-Hall), Southampton, UK P.Little@sot
[Ti] Título:Probiotic capsules and xylitol chewing gum to manage symptoms of pharyngitis: a randomized controlled factorial trial.
[So] Source:CMAJ;189(50):E1543-E1550, 2017 Dec 18.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Reducing the use of antibiotics for upper respiratory tract infections is needed to limit the global threat of antibiotic resistance. We estimated the effectiveness of probiotics and xylitol for the management of pharyngitis. METHODS: In this parallel-group factorial randomized controlled trial, participants in primary care (aged 3 years or older) with pharyngitis underwent randomization by nurses who provided sequential intervention packs. Pack contents for 3 kinds of material and advice were previously determined by computer-generated random numbers: no chewing gum, xylitol-based chewing gum (15% xylitol; 5 pieces daily) and sorbitol gum (5 pieces daily). Half of each group were also randomly assigned to receive either probiotic capsules (containing 24 × 10 colony-forming units of lactobacilli and bifidobacteria) or placebo. The primary outcome was mean self-reported severity of sore throat and difficulty swallowing (scale 0-6) in the first 3 days. We used multiple imputation to avoid the assumption that data were missing completely at random. RESULTS: A total of 1009 individuals consented, 934 completed the baseline assessment, and 689 provided complete data for the primary outcome. Probiotics were not effective in reducing the severity of symptoms: mean severity scores 2.75 with no probiotic and 2.78 with probiotic (adjusted difference -0.001, 95% confidence interval [CI] -0.24 to 0.24). Chewing gum was also ineffective: mean severity scores 2.73 without gum, 2.72 with sorbitol gum (adjusted difference 0.07, 95% CI -0.23 to 0.37) and 2.73 with xylitol gum (adjusted difference 0.01, 95% CI -0.29 to 0.30). None of the secondary outcomes differed significantly between groups, and no harms were reported. INTERPRETATION: Neither probiotics nor advice to chew xylitol-based chewing gum was effective for managing pharyngitis. ISRCTN, no. ISRCTN51472596.
[Mh] Termos MeSH primário: Anti-Infecciosos Locais/uso terapêutico
Goma de Mascar
Faringite/tratamento farmacológico
Probióticos/uso terapêutico
Xilitol/uso terapêutico
[Mh] Termos MeSH secundário: Bifidobacterium bifidum
Criança
Pré-Escolar
Feminino
Seres Humanos
Lactobacillus acidophilus
Masculino
Faringite/prevenção & controle
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Infective Agents, Local); 0 (Chewing Gum); VCQ006KQ1E (Xylitol)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180103
[Lr] Data última revisão:
180103
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.170599


  2 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28814130
[Au] Autor:Katoh T; Maeshibu T; Kikkawa KI; Gotoh A; Tomabechi Y; Nakamura M; Liao WH; Yamaguchi M; Ashida H; Yamamoto K; Katayama T
[Ad] Endereço:a Graduate School of Biostudies , Kyoto University , Kyoto , Japan.
[Ti] Título:Identification and characterization of a sulfoglycosidase from Bifidobacterium bifidum implicated in mucin glycan utilization.
[So] Source:Biosci Biotechnol Biochem;81(10):2018-2027, 2017 Oct.
[Is] ISSN:1347-6947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Human gut symbiont bifidobacteria possess carbohydrate-degrading enzymes that act on the O-linked glycans of intestinal mucins to utilize those carbohydrates as carbon sources. However, our knowledge about mucin type O-glycan degradation by bifidobacteria remains fragmentary, especially regarding how they decompose sulfated glycans, which are abundantly found in mucin sugar-chains. Here, we examined the abilities of several Bifidobacterium strains to degrade a sulfated glycan substrate and identified a 6-sulfo-ß-d-N-acetylglucosaminidase, also termed sulfoglycosidase, encoded by bbhII from Bifidobacterium bifidum JCM 7004. A recombinant BbhII protein showed a substrate preference toward 6-sulfated and 3,4-disulfated N-acetylglucosamines over non-sulfated and 3-sulfated N-acetylglucosamines. The purified BbhII directly released 6-sulfated N-acetylglucosamine from porcine gastric mucin and the expression of bbhII was moderately induced in the presence of mucin. This de-capping activity may promote utilization of sulfated glycans of mucin by other bacteria including bifidobacteria, thereby establishing the symbiotic relationship between human and gut microbes.
[Mh] Termos MeSH primário: Acetilglucosaminidase/metabolismo
Bifidobacterium bifidum/enzimologia
Mucinas/metabolismo
Polissacarídeos/metabolismo
[Mh] Termos MeSH secundário: Acetilglucosaminidase/química
Acetilglucosaminidase/genética
Sequência de Aminoácidos
Bifidobacterium bifidum/genética
Bifidobacterium bifidum/metabolismo
Regulação Bacteriana da Expressão Gênica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mucins); 0 (Polysaccharides); EC 3.2.1.52 (Acetylglucosaminidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1080/09168451.2017.1361810


  3 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28650782
[Au] Autor:Ghasemi E; Mazaheri R; Tahmourespour A
[Ti] Título:Effect of Probiotic Yogurt and Xylitol-Containing Chewing Gums on Salivary S Mutans Count.
[So] Source:J Clin Pediatr Dent;41(4):257-263, 2017.
[Is] ISSN:1053-4628
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: In addition to improving gastrointestinal health and intestinal microflora, probiotic bacteria have been recently suggested to decrease cariogenic agents in the oral cavity. The aim of this study was to investigate the effects of probiotic yogurt and xylitol-containing chewing gums on reducing salivary Streptococcus mutans levels. STUDY DESIGN: This randomized clinical trial recruited 50 female students with over 10 colony forming units S. mutans per milliliter of their saliva. The participants were randomly allocated to two equal groups to receive either probiotic yogurt containing Lactobacillus acidophilus ATCC 4356 andBifidobacteriumbifidum ATCC 29521 (200 g daily) or xylitol-containing chewing gums (two gums three times daily after each meal; total xylitol content: 5.58 g daily) for three weeks. At baseline and one day, two weeks, and four weeks after the interventions, saliva samples were cultured on mitis-salivarius-bacitracin agar and salivary S. mutans counts were determined. Data were analyzed with independent t-tests, analysis of variance, and Fisher's least significant difference test. RESULTS: In both groups, S. mutans counts on the first day, second week, and fourth weeks after the intervention were significantly lower than baseline values (P < 0.05). The greatest level of reduction in both groups was observed in the second week after the intervention. Moreover, although the reduction was greater in probiotic yogurt consumers, the difference between the two groups was not statistically significant. CONCLUSION: Probiotic yogurt and xylitol-containing chewing gums seem to be as effective in reduction of salivary S. mutans levels. Their constant long-term consumption is thus recommended to prevent caries.
[Mh] Termos MeSH primário: Bifidobacterium bifidum
Goma de Mascar
Cárie Dentária/prevenção & controle
Lactobacillus acidophilus
Probióticos/farmacologia
Saliva/microbiologia
Streptococcus mutans/efeitos dos fármacos
Xilitol/farmacologia
Iogurte/microbiologia
[Mh] Termos MeSH secundário: Carga Bacteriana
Ensaio de Unidades Formadoras de Colônias
Cárie Dentária/microbiologia
Feminino
Seres Humanos
Irã (Geográfico)
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Chewing Gum); VCQ006KQ1E (Xylitol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE
[do] DOI:10.17796/1053-4628-41.4.257


  4 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28546425
[Au] Autor:Sato M; Liebschner D; Yamada Y; Matsugaki N; Arakawa T; Wills SS; Hattie M; Stubbs KA; Ito T; Senda T; Ashida H; Fushinobu S
[Ad] Endereço:From the Department of Biotechnology, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
[Ti] Título:The first crystal structure of a family 129 glycoside hydrolase from a probiotic bacterium reveals critical residues and metal cofactors.
[So] Source:J Biol Chem;292(29):12126-12138, 2017 Jul 21.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The α- -acetylgalactosaminidase from the probiotic bacterium (NagBb) belongs to the glycoside hydrolase family 129 and hydrolyzes the glycosidic bond of Tn-antigen (GalNAcα1-Ser/Thr). NagBb is involved in assimilation of -glycans on mucin glycoproteins by in the human gastrointestinal tract, but its catalytic mechanism has remained elusive because of a lack of sequence homology around putative catalytic residues and of other structural information. Here we report the X-ray crystal structure of NagBb, representing the first GH129 family structure, solved by the single-wavelength anomalous dispersion method based on sulfur atoms of the native protein. We determined ligand-free, GalNAc, and inhibitor complex forms of NagBb and found that Asp-435 and Glu-478 are located in the catalytic domain at appropriate positions for direct nucleophilic attack at the anomeric carbon and proton donation for the glycosidic bond oxygen, respectively. A highly conserved Asp-330 forms a hydrogen bond with the O4 hydroxyl of GalNAc in the -1 subsite, and Trp-398 provides a stacking platform for the GalNAc pyranose ring. Interestingly, a metal ion, presumably Ca , is involved in the recognition of the GalNAc -acetyl group. Mutations at Asp-435, Glu-478, Asp-330, and Trp-398 and residues involved in metal coordination (including an all-Ala quadruple mutant) significantly reduced the activity, indicating that these residues and the metal ion play important roles in substrate recognition and catalysis. Interestingly, NagBb exhibited some structural similarities to the GH101 endo-α- -acetylgalactosaminidases, but several critical differences in substrate recognition and reaction mechanism account for the different activities of these two enzymes.
[Mh] Termos MeSH primário: Acetilgalactosamina/metabolismo
Proteínas de Bactérias/metabolismo
Bifidobacterium bifidum/enzimologia
Coenzimas/metabolismo
Glicosídeo Hidrolases/metabolismo
Metais/metabolismo
alfa-N-Acetilgalactosaminidase/metabolismo
[Mh] Termos MeSH secundário: Acetilgalactosamina/química
Sequência de Aminoácidos
Substituição de Aminoácidos
Proteínas de Bactérias/antagonistas & inibidores
Proteínas de Bactérias/química
Proteínas de Bactérias/genética
Sítios de Ligação
Domínio Catalítico
Coenzimas/química
Sequência Conservada
Cristalografia por Raios X
Inibidores Enzimáticos/química
Inibidores Enzimáticos/metabolismo
Inibidores Enzimáticos/farmacologia
Glicosídeo Hidrolases/antagonistas & inibidores
Glicosídeo Hidrolases/química
Glicosídeo Hidrolases/genética
Ligantes
Metais/química
Modelos Moleculares
Mutagênese Sítio-Dirigida
Mutação
Probióticos
Conformação Proteica
Proteínas Recombinantes de Fusão/química
Proteínas Recombinantes de Fusão/metabolismo
Alinhamento de Sequência
Homologia Estrutural de Proteína
alfa-N-Acetilgalactosaminidase/antagonistas & inibidores
alfa-N-Acetilgalactosaminidase/química
alfa-N-Acetilgalactosaminidase/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Coenzymes); 0 (Enzyme Inhibitors); 0 (Ligands); 0 (Metals); 0 (Recombinant Fusion Proteins); EC 3.2.1.- (Glycoside Hydrolases); EC 3.2.1.49 (alpha-N-Acetylgalactosaminidase); KM15WK8O5T (Acetylgalactosamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170527
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M117.777391


  5 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28490394
[Au] Autor:Zamani B; Farshbaf S; Golkar HR; Bahmani F; Asemi Z
[Ad] Endereço:1Department of Gastroenterology,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.
[Ti] Título:Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial.
[So] Source:Br J Nutr;117(8):1095-1102, 2017 Apr.
[Is] ISSN:1475-2662
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Synbiotic intake may be associated with reduced inflammation in patients with rheumatoid arthritis (RA) due to optimised inflammatory markers, oxidative stress and insulin resistance. This research was conducted to assess the effects of synbiotic supplementation on the clinical and metabolic parameters of patients with RA. A total of fifty-four patients with RA were allocated into two groups to receive either a synbiotic capsule (n 27) or a placebo (n 27) for 8 weeks in this randomised, double-blind, placebo-controlled trial. Fasting blood samples were taken at baseline and week 8 of the study to quantify related markers. After the 8-week intervention, compared with the placebo, synbiotic supplementation resulted in a significant reduction in serum high-sensitivity C-reactive protein (hs-CRP) levels (-1427·8 (sd 3267·2) v. +2833·4 (sd 5639·7) ng/ml, P=0·001). In addition, compared with the placebo, synbiotic supplementation improved disease activity score-28 joints (DAS-28) (-1·6 (sd 0·8) v. -0·3 (sd 0·5), P<0·001) and visual analogue scales (VAS) pain (-30·4 (sd 18·7) v. -11·5 (sd 15·9), P<0·001). In addition, a significant elevation in plasma nitric oxide (NO) (+0·8 (sd 4·4) v. -2·6 (sd 4·5) µmol/l, P=0·008), and significant reductions in insulin values (-13·8 (sd 26·4) v. +4·2 (sd 28·2) pmol/l, P=0·01), homoeostasis model of assessment-estimated insulin resistance (HOMA-IR) (-0·5 (sd 1·0) v.+0·1 (sd 1·1), P=0·03) and homoeostatic model assessment-ß-cell function (HOMA-B) (-9·4 (sd 17·9) v. +3·3 (sd 18·9), P=0·01) following supplementation with the synbiotic compared with the placebo. Compared with the placebo, synbiotic supplementation also resulted in a significant increase in plasma GSH (+36·6 (sd 63·5) v. -58·5 (sd 154·4) µmol/l, P=0·005). Overall, our study demonstrated that synbiotic supplementation for 8 weeks among patients with RA had beneficial effects on hs-CRP, DAS-28, VAS, NO, insulin levels, HOMA-IR, HOMA-B and GSH levels.
[Mh] Termos MeSH primário: Artrite Reumatoide/terapia
Bifidobacterium bifidum
Suplementos Nutricionais
Lactobacillus acidophilus
Lactobacillus casei
Simbióticos
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios/uso terapêutico
Antirreumáticos/uso terapêutico
Método Duplo-Cego
Feminino
Seres Humanos
Hidroxicloroquina/uso terapêutico
Masculino
Metotrexato/uso terapêutico
Meia-Idade
Prednisolona/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antirheumatic Agents); 4QWG6N8QKH (Hydroxychloroquine); 9PHQ9Y1OLM (Prednisolone); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE
[do] DOI:10.1017/S000711451700085X


  6 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28383398
[Au] Autor:Xiao L; Ding G; Ding Y; Deng C; Ze X; Chen L; Zhang Y; Song L; Yan H; Liu F; Ben X
[Ad] Endereço:aDepartment of Neonatology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China bDepartment of Pediatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China cBiostime Institute for Nutrition and Care, Biostime Co. Ltd., Guangzhou, China dDepartment of Food Science and Engineering, Shanghai Jiao Tong University, Shanghai, China eDepartment of Laboratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China.
[Ti] Título:Effect of probiotics on digestibility and immunity in infants: A study protocol for a randomized controlled trial.
[So] Source:Medicine (Baltimore);96(14):e5953, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The gastrointestinal (GI) tract of a fetus in utero is sterile but it becomes colonized with environmental microorganisms shortly after birth. Since the gut microbiota undergoes substantial changes in early life, healthy gut microflora is essential to an infant's gut health and immune system and probably also has an effect on overall health status in later life. Probiotics, defined as viable microbial preparations that have a beneficial effect on the health of the host, represent a rapidly expanding field. Although randomized controlled trials using probiotics in infants have shown promising results in the prevention and treatment of common diseases such as diarrhea and allergy, little is known about whether probiotics could offer benefits to healthy infants. We have designed a randomized controlled trial to test the hypothesis that an oral preparation of probiotics is superior to placebo in improving digestive and immune function in healthy infants.The trial will be a randomized, double-blind, placebo-controlled, 2-parallel-group study in Shanghai, China. After a 2-week run-in period, 200 exclusively formula-fed healthy infants aged 4 to 6 months will be randomly allocated to receive either a probiotic product containing Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052 or an identical placebo once daily for 4 weeks and will be followed up for 8 weeks. The duration of the subject's participation will be 14 weeks, with a total of 5 visits: inclusion (Visit 1, Day 1), start of intervention (V2, D15), end of intervention (V3, D44), and follow-up (V4 and V5, D72 and D100). Stool and saliva samples will be collected at the first 3 visits to measure microbial populations and secretory immunoglobulin A (SIgA), respectively. Physical examination will be performed at each visit, and tolerance records will be completed 1 day prior to each visit. The primary endpoints will be the changes in the composition of fecal microbiota, particularly the Bifidobacterium bifidum population. The secondary endpoints will include the change in salivary SIgA level, growth parameters, digestive tolerance, and adverse events.An effective, practical, and acceptable probiotic intervention in manipulating the gut microbiota and boosting the immune system in formula-fed infants would represent a major clinical advance. The administration of probiotic supplementation or follow-on formula to infant may be associated with some clinic benefits.
[Mh] Termos MeSH primário: Digestão/efeitos dos fármacos
Imunidade/efeitos dos fármacos
Probióticos/uso terapêutico
[Mh] Termos MeSH secundário: Bifidobacterium bifidum
Bifidobacterium longum subspecies infantis
Protocolos Clínicos
Método Duplo-Cego
Fezes/microbiologia
Seres Humanos
Imunoglobulina A Secretora/análise
Lactente
Lactobacillus helveticus
Seleção de Pacientes
Probióticos/farmacologia
Saliva/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Immunoglobulin A, Secretory)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000005953


  7 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28346473
[Au] Autor:Kawahara T; Makizaki Y; Oikawa Y; Tanaka Y; Maeda A; Shimakawa M; Komoto S; Moriguchi K; Ohno H; Taniguchi K
[Ad] Endereço:R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan.
[Ti] Título:Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors.
[So] Source:PLoS One;12(3):e0173979, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human rotavirus (RV) infection is a leading cause of dehydrating diarrhea in infants and young children worldwide. Since therapeutic approaches to RV gastroenteritis are limited to alleviation of dehydration with oral rehydration solutions, more direct approaches to palliate symptoms of RV gastroenteritis are required. Treatments with probiotics have been increasingly recognized as alternative safe and low cost treatments for moderate infectious diarrhea. In this study, Bifidobacterium bifidum G9-1 (BBG9-1), which has been used as an intestinal drug for several decades, was shown to have a remarkable protective effect against RV gastroenteritis in a suckling mice model. As well as prophylactic oral administration of BBG9-1 from 2 days before RV infection, therapeutic oral administration of BBG9-1 from 1 day after RV infection significantly alleviated RV-induced diarrhea. Therapeutic administration of BBG9-1 reduced various types of damage in the small intestine, such as epithelial vacuolization and villous shortening, and significantly diminished the infectious RV titer in mixtures of cecal contents and feces. It was also shown that therapeutic administration of BBG9-1 significantly increased the number of acidic mucin-positive goblet cells and the gene expression of mucosal protective factors including MUC2, MUC3, MUC4, TGFß1 and TFF3 in the small intestine. This led to alleviation of low gut permeability shown as decreased gene expression levels of occludin, claudin-1 and villin-1 after RV infection. Furthermore, in the small intestine, therapeutic administration of BBG9-1 significantly palliated the decreased gene expression of SGLT-1, which plays an important role in water absorption. In the large intestine, administered BBG9-1 was shown to replicate to assimilate undigested nutrients, resulting in normalization of the abnormally high osmotic pressure. These results suggested that water malabsorption caused by RV infection was alleviated in mice administered BBG9-1. Thus, the present study showed that oral administration of BBG9-1 palliated diarrhea partly through protection against RV-induced lesions by inducing mucosal protective factors. Oral administration of BBG9-1 is thought to be an efficient method for management of an RV epidemic for both prophylactic and therapeutic purposes.
[Mh] Termos MeSH primário: Bifidobacterium bifidum/fisiologia
Gastroenterite/terapia
Intestinos/microbiologia
Intestinos/patologia
Probióticos/uso terapêutico
Infecções por Rotavirus/terapia
[Mh] Termos MeSH secundário: Administração Oral
Animais
Linhagem Celular
Cercopithecus aethiops
Diarreia/complicações
Diarreia/microbiologia
Diarreia/patologia
Diarreia/terapia
Gastroenterite/complicações
Gastroenterite/microbiologia
Gastroenterite/patologia
Regulação da Expressão Gênica
Macaca mulatta
Camundongos Endogâmicos BALB C
Probióticos/administração & dosagem
Rotavirus/isolamento & purificação
Rotavirus/fisiologia
Infecções por Rotavirus/complicações
Infecções por Rotavirus/microbiologia
Infecções por Rotavirus/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0173979


  8 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28259400
[Au] Autor:Yang D; Wu X; Yu X; He L; Shah NP; Xu F
[Ad] Endereço:State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, Jiangxi, 330047, P. R. China.
[Ti] Título:Mutual growth-promoting effect between Bifidobacterium bifidum WBBI03 and Listeria monocytogenes CMCC 54001.
[So] Source:J Dairy Sci;100(5):3448-3462, 2017 May.
[Is] ISSN:1525-3198
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, Bifidobacterium bifidum WBBI03 and Listeria monocytogenes CMCC 54001 were selected to detect the changes in their growth pattern after mutual interaction between them. The proteomic changes after the interaction between the 2 bacteria were detected by the isobaric tags for relative and absolute quantitation method. The proteins related to the biosynthesis and cell reproduction were selected, and their changes at the transcriptional level were monitored by fluorescent quantitative PCR. Also, 3 other types of probiotic organisms and opportunistic pathogens were used to verify the results mentioned above. The results showed that growing the 2 organisms together could promote the growth of each other, resulting in earlier entry into the logarithmic phase. The results also showed that the expression of these proteins mostly tended to be upregulated at the translational and transcriptional level. The increase in the expression of these proteins might help promote the growth and reproduction of B. bifidum WBBI03 and L. monocytogenes CMCC 54001. One aspect of the biological significance of their presence in the normal intestine may be that the opportunistic pathogens promote the growth of the probiotics.
[Mh] Termos MeSH primário: Bifidobacterium bifidum/fisiologia
Listeria monocytogenes/fisiologia
[Mh] Termos MeSH secundário: Animais
Probióticos/metabolismo
Proteômica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170522
[Lr] Data última revisão:
170522
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170306
[St] Status:MEDLINE


  9 / 36 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28245626
[Au] Autor:Tanaka K; Tsukahara T; Yanagi T; Nakahara S; Furukawa O; Tsutsui H; Koshida S
[Ad] Endereço:Department of Pediatrics, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. tanakatsu0124@gmail.com.
[Ti] Título:Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study.
[So] Source:Nutrients;9(3), 2017 Feb 26.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Probiotic supplementation has been part of the discussion on methods to enhance humoral immunity. Administration of OLB6378 (OLB6378) reduced the incidence of late-onset sepsis in infants. In this non-randomized study, we aimed to determine the effect of administration of live OLB6378 on infants' humoral immunity. Secondly, we tried to elucidate whether similar effects would be observed with administration of non-live OLB6378. Low birth weight (LBW) infants weighing 1500-2500 g were divided into three groups: Group N (no intervention), Group L (administered live OLB6378 concentrate), and Group H (administered non-live OLB6378 concentrate). The interventions were started within 48 h after birth and continued until six months of age. Serum immunoglobulin G (IgG) levels (IgG at one month/IgG at birth) were significantly higher in Group L than in Group N ( < 0.01). Group H exhibited significantly higher serum IgG levels ( < 0.01) at one month of age and significantly higher intestinal secretory immunoglobulin A (SIgA) levels ( < 0.05) at one and two months of age than Group N. No difference was observed in the mortality or morbidity between groups. Thus, OLB6378 administration in LBW infants enhanced humoral immunity, and non-live OLB6378, which is more useful as a food ingredient, showed a more marked effect than the viable bacteria.
[Mh] Termos MeSH primário: Bifidobacterium bifidum
Imunidade Humoral
Imunidade nas Mucosas
Recém-Nascido de Baixo Peso/imunologia
Probióticos/administração & dosagem
Sepse/prevenção & controle
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Imunoglobulina G/sangue
Incidência
Lactente
Masculino
Ensaios Clínicos Controlados não Aleatórios como Assunto
Manejo de Espécimes
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE


  10 / 36 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28237995
[Au] Autor:Youn SY; Ji GE; Han YR; Park MS
[Ad] Endereço:Animal and Plant Quarantine Agency, Gimcheon 39660, Republic of Korea.
[Ti] Título:Development of Strain-Specific Primers for Identification of BGN4.
[So] Source:J Microbiol Biotechnol;27(5):909-915, 2017 May 28.
[Is] ISSN:1738-8872
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:BGN4 (BGN4) has many proven beneficial effects, including antiallergy and anticancer properties. It has been commercialized and used in several probiotic products, and thus strain-specific identification of this strain is very valuable for further strain-dependent physiological study. For this purpose, we developed novel multiplex polymerase chain reaction (PCR) primer sets for strain-specific detection of BGN4 in commercial products and fecal samples of animal models. The primer set was tested on seven strains of and 75 strains of the other species. The BGN4-specific regions were derived using megaBLAST against genome sequences of various databases and four sets of primers were designed. As a result, only BGN4 produced four PCR products simultaneously whereas the other strains did not. The PCR detection limit using BGN4-specific primer sets was 2.8 × 10 CFU/ml of BGN4. Those primer sets also detected and identified BGN4 in the probiotic products containing BNG4 and fecal samples from a BGN4-fed animal model with high specificity. Our results indicate that the PCR assay from this study is an efficient tool for the simple, rapid, and reliable identification of BGN4, for which probiotic strains are known.
[Mh] Termos MeSH primário: Bifidobacterium bifidum/genética
Bifidobacterium bifidum/isolamento & purificação
Primers do DNA/genética
Reação em Cadeia da Polimerase Multiplex/métodos
[Mh] Termos MeSH secundário: Animais
Sequência de Bases
DNA Bacteriano/genética
Fezes/microbiologia
Camundongos
Camundongos Endogâmicos C57BL
Modelos Animais
Probióticos
Especificidade da Espécie
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA Primers); 0 (DNA, Bacterial)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170227
[St] Status:MEDLINE
[do] DOI:10.4014/jmb.1610.10018



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde